Tirzepatide is the youngest of the major GLP-1-class peptides — and arguably the most effective weight-loss drug ever approved. If semaglutide redefined what was possible, tirzepatide pushed the ceiling higher.
This guide covers what tirzepatide is, why it's a different molecule than semaglutide, how it's dosed, what to expect, and how it stacks up against the alternatives. Every section links to a deeper question.
What tirzepatide actually is
Tirzepatide is a dual-agonist peptide — meaning it activates two different receptors that other weight-loss drugs only hit one of.
- GLP-1 receptor — same target as semaglutide; reduces appetite, slows gastric emptying, signals fullness
- GIP receptor — short for "glucose-dependent insulinotropic polypeptide"; another gut hormone that amplifies insulin secretion and may improve how your fat tissue responds to insulin
The combination is more than the sum of the parts. In trials, tirzepatide produces noticeably larger weight reductions than GLP-1 monotherapy at every comparable dose.
It's a once-weekly injection, made by Eli Lilly, sold as either:
| Brand | FDA-approved use | Dose range |
|---|---|---|
| Mounjaro | Type 2 diabetes | 2.5 → 15 mg |
| Zepbound | Chronic weight management | 2.5 → 15 mg |
Both pens contain identical tirzepatide at identical strengths. The only practical differences are the label, the insurance billing path, and sometimes the price. See our Mounjaro vs Zepbound cluster for the deeper breakdown.
Why dual agonism matters
For decades, the GLP-1 pathway was the incretin target. Drugs from exenatide to liraglutide to semaglutide each hit GLP-1 alone, with each generation getting better at activating it for longer.
GIP was historically considered uninteresting — even unhelpful in obesity, because GIP secretion is elevated in people with insulin resistance. The conventional wisdom was: blocking GIP might help weight loss.
Tirzepatide flipped that view. By activating GIP alongside GLP-1, it produced bigger weight reductions than either pathway alone. Why? The leading hypothesis is that chronic GIP receptor activation desensitizes the receptors over time — effectively quieting the same signaling that was thought to be pro-obesity in the untreated state.
For the full mechanism breakdown, see how tirzepatide works.
How tirzepatide is dosed
Standard titration covers six dose levels, increasing every 4 weeks:
| Weeks | Weekly dose |
|---|---|
| 1–4 | 2.5 mg (starting) |
| 5–8 | 5 mg |
| 9–12 | 7.5 mg |
| 13–16 | 10 mg |
| 17–20 | 12.5 mg |
| 21+ | 15 mg (maintenance) |
Many people stop at 5, 7.5, or 10 mg and stay there if they're seeing the response they want — there's no requirement to push to 15 mg. The same logic applies in reverse: if a step gives you rough side effects, hold for an extra 2–4 weeks before stepping up. Our when to step up tirzepatide cluster has a decision framework.
Tirzepatide injects once weekly into the abdomen, thigh, or upper arm. Rotate sites with every injection.
Compounded tirzepatide is dosed identically by milligram, but you're drawing your own units from a reconstituted vial — see our calculator for the math, and the compounded tirzepatide cluster for what to look for in a compounder.
Side effects
Tirzepatide's side-effect profile looks similar to semaglutide's, with one notable difference: constipation is more common, and nausea is sometimes slightly less pronounced.
The usual GI suspects:
- Nausea — peaks the week after each dose increase, fades within 1–2 weeks
- Constipation — often the most persistent side effect; needs proactive fiber and hydration
- Diarrhea (less common, often in early titration)
- Reflux and heartburn
- Fatigue in the first weeks
- Decreased appetite — the desired mechanism, occasionally over-suppressing
Less common: pancreatitis, gallbladder issues, thyroid C-cell concerns (the same black-box warning as semaglutide). Hair loss can occur with rapid weight loss but isn't tirzepatide-specific.
For a comparison of how the side-effect profiles differ between the two peptides, see tirzepatide side effects vs semaglutide. For coping strategies, see our side effects pillar — every complaint, every fix.
What the trial data shows
The SURMOUNT program (weight management) and SURPASS program (T2D) are the trial families behind tirzepatide's labels.
SURMOUNT-1 headline numbers (people with obesity, no diabetes):
| Dose | Mean weight loss at 72 weeks |
|---|---|
| 5 mg | 16.0% |
| 10 mg | 21.4% |
| 15 mg | 22.5% |
| Placebo | 2.4% |
For context, semaglutide at 2.4 mg in STEP-1 produced 14.9% loss over 68 weeks. Tirzepatide at 5 mg already exceeds that.
SURPASS (T2D) showed A1c reductions of 1.9–2.4 percentage points across doses, generally outperforming semaglutide head-to-head.
Our SURMOUNT trial results cluster goes deeper, including subgroup analyses and what to make of the placebo response.
Tirzepatide vs semaglutide
The most-asked tirzepatide question. Short version:
| Semaglutide | Tirzepatide | |
|---|---|---|
| Mechanism | GLP-1 only | GLP-1 + GIP |
| Top dose | 2.4 mg (Wegovy) | 15 mg |
| Weight loss in trial | ~15% | ~22% |
| Cadence | Weekly | Weekly |
| GI side effects | Slightly higher nausea | Slightly higher constipation |
| Brand cost (US) | $1,000–1,400/mo | $1,000–1,400/mo |
| Compounded availability | Common | Common |
For most people the practical answer is "whichever your insurance covers, or whichever your provider recommends based on side-effect history." If you have free choice, tirzepatide tends to produce slightly more weight loss with similar tolerability. See our full tirzepatide vs semaglutide breakdown for the nuance.
Who tirzepatide is right for
Tirzepatide is approved for:
- Adults with type 2 diabetes (Mounjaro)
- Adults with BMI ≥ 30, or BMI ≥ 27 with a weight-related comorbidity (Zepbound)
Same contraindications as semaglutide: avoid in pregnancy, personal/family history of medullary thyroid carcinoma or MEN-2, active pancreatitis. Always a clinician-led decision.
Where to go next
The questions below are what tirzepatide users — and prospective users — are actually searching for. Each one is its own dedicated page.